Spencer David M. 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Jan 5, 2018
Insider Transaction Report
Form 4
Spencer David M.
Chief Scientific Officer
Transactions
- Tax Payment
Common Stock
2018-01-03$9.79/sh−589$5,766→ 139,939 total - Exercise/Conversion
Common Stock
2018-01-03+1,563→ 140,528 total - Exercise/Conversion
Restricted Stock Units
2018-01-03−1,563→ 4,687 total→ Common Stock (1,563 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on January 3, 2018, to satisfy tax withholding obligations that arose in connection with the vesting of the RSUs granted to the reporting person on January 3, 2017 for 6,250 shares.
- [F3]On January 3, 2017, the reporting person was granted 6,250 RSUs, of which 1,563 vested on January 3, 2018. The RSUs vest in four equal annual installments beginning January 3, 2018.